Francis will lead Actuate’s continued global expansion, strengthen its channel partnerships, and advance its position as a ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment ...

Read Less In this article, we consider the case for investing in UK funds. We’ve also asked Rob Morgan, investment analyst at wealth managers, Charles Stanley, to identify five UK funds suitable ...

Since the end of World War Two, immigration has transformed the UK. After the war, fewer than one in 25 of the population had been born outside the country; today that figure is closer to one in ...

Like it - or not - it has been three years since the UK left the European Union. Since then there has been a pandemic, swiftly followed by an energy crisis. That has made it hard to decipher ...

Actuate, a global provider of vision-based AI monitoring solutions, has announced the appointment of Ken Francis as CEO.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product ...

This page features the latest news about the Actuate Therapeutics stock. Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development Companies will discuss how Lantern's AI ...

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...